Zoetis Inc. stock underperforms Thursday when compared to competitors
Zoetis Inc. (ZTS) shares fell by 5.59% to $80.79 on Thursday, underperforming the broader market as the S&P 500 Index dropped 2.02% and the Dow Jones Industrial Average fell 2.19%. The company's stock closed 39.02% below its 52-week high of $132.49.
Rep. Byron Donalds Sells Netflix Stock for Loss: Here’s What He’s Buying Instead
Rep. Byron Donalds (R-Fla.) recently disclosed stock trades made in October, selling shares in Autodesk, Zoetis, and Netflix, while buying Interactive Brokers stock. Donalds incurred losses on his Autodesk and Netflix sales, making a small profit on Zoetis. Upon becoming governor of Florida, Donalds will no longer be required to report his stock trades every 45 days.
Lame, suffocated and dead: The drug supersizing America’s cattle
Elanco Animal Health's drug Experior, approved by the FDA to reduce ammonia emissions in cattle, is now a major profit driver due to its off-label growth-promoting effects, despite concerns about animal welfare. The drug has been linked to increased lameness, bloat, and deaths in cattle in both studies and real-world feedlots. Critics point to the FDA's approval process and the influence of pharmaceutical companies and academia on the livestock industry, raising questions about drug safety and transparency.
Alpha Teknova, Inc. Common Stock (TKNO) Stock Price: Nov 12 Close $8.30
Alpha Teknova, Inc. (TKNO) closed at $8.21 on November 13, 2026. The article provides an overview of TKNO's stock performance, key financial metrics, analyst ratings with a "Buy" consensus, and recent news including a 5.1% jump and insider buying. It also details the company's profile, product categories, and key executives.
Weekly Recap: Mixed Q3 results and canine treatment authorizations
Zoetis (ZTS) reported a mixed Q3 with revenue down 1% to $2.391 billion, but adjusted EPS rose 3% to $1.75, leading to an increase in EPS guidance despite a share price drop. The company also secured FDA approval for Convenia RTU for Dogs and emergency authorization for Simparica Trio, along with launching new treatments for canine and feline osteoarthritis in other markets. Additionally, Zoetis highlighted its existing dog allergy treatments, Apoquel and Cytopoint.
Farm Hands on the Potomac: Vylor names Kurt Van Thomme, The Animal Health Institute hires Andrew Bailey, Kinzie Davis joins Elanco
This article details recent personnel changes in the agricultural and food industries. Key appointments include Kurt Van Thomme at Vylor, Andrew Bailey at The Animal Health Institute, and Kinzie Davis at Elanco, along with numerous other leadership shifts across various companies such as Sonoco, Zoetis, American Beverage, UPSIDE Foods, ADS Produce, World Food Programme, MustGrow Biologics, and Hudsonville Ice Cream. The "Farm Hands West" section also covers appointments at the University of Arizona, U.S. Highbush Blueberry Council, Interra International, and Allen Lund Co., alongside departures and new roles at Driscoll's, American Agricultural Law Association, DMA Solutions, and PepsiCo.
Pet health spending remains ‘nonnegotiable’ priority, survey finds
A recent Elanco survey indicates that pet owners consider animal health spending a non-negotiable priority, even amid economic pressures, with 93% maintaining or increasing their spending. While medication purchases are shifting away from veterinary clinics to other retail channels, veterinarians' recommendations remain the primary influence on product selection. Future demand for pet ownership also appears strong, with 25% of current owners planning to adopt another pet within the next year.
Zoetis Demonstrates Credible Efforts To Play Defense in Face of Heightened Competition
Zoetis, the leading global animal health company, is making efforts to maintain its market position against increasing competition. The company's strategy focuses on innovation across its product portfolio, including new drugs for pet ailments and a promising pipeline of monoclonal antibodies for canine and feline diseases. Morningstar acknowledges Zoetis's strong economic moat due to its impressive innovation and market leadership.
Why this money manager is buying S&P Global and Berkshire Hathaway
Daymon Loeb, CEO of Ravenstone Capital Management, is focusing on "boring, traditional businesses" with strong fundamentals and reasonable valuations, rather than the AI trade. He has recently bought S&P Global (SPGI-N) due to its dominant market position and attractive valuation despite AI disruption fears, and Berkshire Hathaway (BRK-B-N), believing the market undervalues its intrinsic value and new CEO Greg Abel's leadership. Mastercard (MA-N) is another recent purchase, valued for its global duopoly in payment systems and lack of credit risk.
Zoetis Earnings: Firm Executes Hard Pivot To Play Defense; Raising Our Fair Value Estimate
Zoetis reported third-quarter results with operational revenue falling 1% to $2.39 billion and adjusted diluted EPS up 3% to $1.75, both exceeding FactSet consensus estimates. Despite this, shares closed down 8% on November 5, likely due to management's cautious outlook for 2027. Morningstar is raising its fair value estimate for Zoetis, acknowledging the firm's strategic shift to a defensive posture amidst competitive pressures.
Zoetis Inc earnings beat by $0.24, revenue topped estimates
Zoetis Inc (NYSE: ZTS) reported third-quarter earnings per share (EPS) of $1.75, surpassing analyst estimates by $0.24, and revenue of $2.4 billion, exceeding the consensus estimate of $2.3 billion. The company provided fiscal year 2026 guidance, expecting EPS between $6.25 and $6.35 and revenue between $9.22 billion and $9.32 billion. Zoetis Inc's stock has shown a 22.76% increase over the last three months but a 25.39% decrease over the past year.
Zoetis Q3FY26 Results: Adjusted EPS rises 3% to $1.75, guidance raised
Zoetis reported Q3 2026 revenue of $2.4 billion, a 1% decrease year-over-year, with adjusted diluted EPS rising 3% to $1.75. The company's U.S. segment revenue declined 6%, while international segment revenue grew 4%. Zoetis raised its full-year 2026 adjusted diluted EPS guidance to $6.25–$6.35.
Marea Therapeutics to present at major November investor conferences on new cardioendocrine drug developments
Marea Therapeutics, a subsidiary of Lisata Therapeutics, will present at major investor conferences in November, including the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference. The company will provide updates on its lead drug candidates, MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly, both in clinical development. Webcasts of these presentations will be available on Lisata's investor website to inform investors about the progress and future plans for these cardioendocrine disease treatments.
Hahn Capital Management LLC Makes New $4.49 Million Investment in Miami International Holdings, Inc. $MIAX
Hahn Capital Management LLC initiated a new $4.49 million investment in Miami International Holdings, Inc. (NYSE:MIAX) during the third quarter, acquiring 134,065 shares. This stake now constitutes 2.6% of Hahn Capital Management's portfolio. Miami International Holdings recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.45 and a 243.6% year-over-year revenue increase to $376.18 million.
Freshpet, Inc. Announces Q3 2026 Financial Results in SEC 8-K Filing
Freshpet, Inc. (NASDAQ:FRPT) filed a Form 8-K with the SEC on November 4, 2026, disclosing its financial results for the quarter ended September 30, 2026. The filing included a press release, an investor presentation, and a transcript from its earnings call, which discussed non-GAAP financial measures reconciled to GAAP. The report was signed by CFO John G. O'Connor.
Zoetis Inc. stock outperforms competitors on strong trading day
Shares of Zoetis Inc. (ZTS) advanced 7.48% to $89.20 on Wednesday, outperforming the broader market. The S&P 500 Index (SPX) rose 1.58%, and the Dow Jones Industrial Average (DJIA) gained 3.03% on the same strong trading day. Despite this gain, Zoetis Inc. remains 32.67% below its 52-week high of $132.49, achieved on February 12th.
(ZTS) Risk Channels and Responsive Allocation
This report analyzes Zoetis Inc. Class A (NYSE: ZTS), identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a breakout underway with compelling upside potential due to no remaining resistance levels above the current price. The analysis provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop levels.
Zoetis Inc. stock outperforms competitors on strong trading day
Shares of Zoetis Inc. (ZTS) rose 4.34% to $83.18 on Monday, outperforming its competitors. This gain occurred during a mixed trading session where the Dow Jones Industrial Average increased, but the S&P 500 Index declined. This marks the stock's third consecutive day of gains.
IDEXX Raises Its Growth Outlook A Third Time As Diagnostics Volumes Outrun Falling Vet Visits, While CoVet Trims The Margin Guide
IDEXX Laboratories reported strong Q3 2026 results, beating earnings and revenue estimates and raising its full-year growth outlook for the third time, driven by robust diagnostics volumes despite declining U.S. vet visits. While core diagnostics accelerated, the acquisition of CoVet and its associated costs led to a slight trim in the company's operating margin guidance, creating a point of scrutiny for investors heading into 2027. The company's innovation pipeline, particularly inVue Dx placements and new cancer diagnostic panels, continues to fuel its growth story.
Europe Dog Dewormers Market Companies, Size & Trends 2026-2035
The Europe dog dewormers market is projected to grow from USD 596.40 million in 2026 to USD 1,222.34 million by 2035, at a CAGR of 8.30%. This growth is driven by rising dog ownership, increased veterinary recommendations for regular deworming, and a shift towards higher-priced monthly combination products. Germany currently dominates the market, while Poland is expected to be the fastest-growing country, fueled by increasing pet care spending and veterinary visits.
Quest Diagnostics Incorporated Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Quest Diagnostics (NYSE:DGX) recently reported third-quarter results, exceeding statutory profit expectations with US$2.78 per share, though revenues were in line with forecasts. Analysts have since updated their models, reaffirming a price target of US$255 and projecting reasonable growth for 2027, with no major changes to their overall outlook for the business. The company is expected to grow its revenue at a rate similar to the broader industry.
Zoetis, Inc. Class A Estimates – BX:ZOE
This article provides an overview of financial estimates for Zoetis, Inc. Class A (ZOE) on the BX Swiss exchange. It highlights the availability of reported financial data and analyst estimates across various financial statements and valuation metrics. Users can explore income statements, balance sheets, and cash flow data, comparing actual results with average, high, and low estimates.
Associated Banc-Corp Reports Third Quarter 2026 Earnings of $0.76 Per Common Share, or $0.81 Per Common Share¹ Excluding Nonrecurring Items Recognized During the Quarter
Associated Banc-Corp reported net income of $144 million, or $0.76 per common share, for Q3 2026, or $0.81 per common share excluding nonrecurring items related to the American National Corporation acquisition. The company highlighted strong core customer deposit growth, net interest margin expansion, and fee income growth, leading to $100 million in share repurchases. Associated Banc-Corp maintains a strong capital position with a CET1 capital ratio of 10.38% and expects continued growth into 2027.
NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?
This article compares Neogen Corporation (NEOG) and Where Food Comes From, Inc. (WFCF), two companies in the food safety industry, to determine which has better investment prospects. It analyzes their business models, financial performance, growth opportunities, and challenges. While NEOG shows stronger growth potential and operational improvement, WFCF offers a more conservative financial profile with less debt.
Why is Elanco Animal Health stock down 5% today? By Investing.com
Elanco Animal Health (ELAN) stock dropped 5% in pre-open trading after Jefferies downgraded it from Buy to Hold and cut its price target to $24 from $31. The downgrade was due to increasing risks to pricing power in the animal health industry, with Jefferies noting that pricing tailwinds are fading and pet owner sentiment is softening. Concerns were further amplified by a similar downgrade for Zoetis and a routine insider share sale.
Eloxx Pharmaceuticals adds Geno Germano to board of directors
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has announced the appointment of Geno Germano to its board of directors. Germano brings over 35 years of biopharmaceutical industry experience, including leadership roles at Pfizer and Wyeth, and currently serves on the boards of several other biopharmaceutical companies. Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare kidney diseases.
Eloxx Pharmaceuticals adds Geno Germano to board of directors By Investing.com
Eloxx Pharmaceuticals, Inc. announced the appointment of Geno Germano to its board of directors. Germano brings over 35 years of biopharmaceutical industry experience, including leadership roles at Pfizer, Wyeth, Elucida Oncology, and Intrexon Corporation. Eloxx is a clinical-stage biopharmaceutical company focusing on rare kidney and dermatological diseases.
Veeco Instruments Inc. (NASDAQ:VECO) Stock Now Rated "Hold" by Sell-Side Brokerages
Seven brokerages covering Veeco Instruments Inc. (NASDAQ:VECO) have given it an average "Hold" recommendation, with four analysts rating it a hold and three recommending a buy, and an average 12-month price target of $52.00. The company recently reported strong quarterly results, beating earnings estimates with $0.33 per share, and experienced significant insider stock sales by its CFO and CEO under Rule 10b5-1 plans. Institutional investors have actively adjusted their positions in the semiconductor company, which currently has a market capitalization of $2.67 billion.
Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks
This article reviews the Q2 earnings performance of pharmaceutical stocks, highlighting Elanco (NYSE:ELAN) as an outperformer with significant revenue and EPS beats. It also examines Bristol-Myers Squibb (NYSE:BMY) for its strong financial results despite a stock dip, Zoetis (NYSE:ZTS) for its weaker performance, and Merck (NYSE:MRK) and ANI Pharmaceuticals (NASDAQ:ANIP) for their mixed results. The article emphasizes the sector's growth drivers, such as precision medicine and AI, alongside challenges like drug pricing pressure and biosimilar competition.
Kabeer Aziz Acquires 2,465 Shares of AN2 Therapeutics at No Cost Under Director Compensation Plan
Director Kabeer Aziz acquired 2,465 shares of AN2 Therapeutics, Inc. (NASDAQ:ANTX) common stock on October 12, 2026, at no cost, as part of the company's non-employee director compensation program. These shares vested immediately and increased his direct holdings to 61,571, with additional indirect holdings through two Adjuvant funds totaling 2,373,500 shares. The transaction was reported in a Form 4 filing with the SEC on October 13, 2026.
Why Did AllianceBernstein (NYSE:AB) Fall Despite Revenue Growth?
AllianceBernstein (NYSE:AB) recently reached a new annual trading low despite reporting year-over-year revenue growth. This decline was attributed to a reduction in its stated share objective, quarterly results that fell slightly below expectations, and a cut in its quarterly dividend. The asset manager's performance reflects broader financial market conditions affecting client activity and investment product demand.
Reducing Zoetis' Fair Value Estimate in Face of Rising Competition; Wide Moat Remains Intact
Morningstar has reduced its fair value estimate for Zoetis due to increasing competitive pressures in the animal health industry. Despite the rising competition, the company maintains its "wide moat" rating, affirming its strong competitive advantage. Zoetis remains a leader in the global animal health sector, distinguished by its innovative product portfolio and promising pipeline, including treatments for various pet ailments and canine cancers.
Zoetis: Reducing Our Valuation to Reflect Greater Competitive Pressure, but Moat Remains Intact
Morningstar has reduced its valuation for Zoetis (ZTS) due to increased competitive pressure in 2026 and 2027. New product launches from Elanco and Merck are directly challenging Zoetis' key dermatology portfolio and its flagship parasiticide, Simparica Trio. Despite this, Morningstar believes Zoetis' economic moat remains intact.
Neogen Shifts Focus to Scale Profitable Growth
Neogen Corp. (NASDAQ: NEOG) reported better-than-expected first-quarter fiscal 2027 financial results, with adjusted earnings beating consensus estimates and sales up 6.5% year over year. The company's focus has shifted to scaling fundamentals for more consistent execution and profitable growth, leading to raised fiscal 2027 guidance for both sales and adjusted EBITDA. Despite positive financial results, Neogen's stock fell on Wednesday.
Elanco Animal Health Reports Q2 2026 Results: Full Earnings Call Transcript
Elanco Animal Health reported strong Q2 2026 results, with 8% organic constant currency revenue growth, outperforming guidance for revenue, adjusted EBITDA, and adjusted EPS. The company was driven by strong performance in U.S. Pet Health and U.S. Farm Animal, led by innovative products like Zenrelia and Credelio Quattro, leading to increased full-year guidance for both top and bottom lines. Elanco is also progressing faster than planned on debt reduction and expects to reach a net leverage ratio of approximately three times by year-end.
Neogen Shifts Focus to Scale Profitable Growth
Neogen (NEOG) reported better-than-expected first-quarter 2027 financial results, with adjusted earnings and sales surpassing consensus estimates. The company raised its fiscal year 2027 guidance for both sales and adjusted EBITDA, reflecting confidence in its continued growth and operational improvements. This positive outlook comes as Neogen shifts its focus from strengthening fundamentals to scaling them for more consistent execution and profitable growth across its Food Safety and Animal Safety segments.
Revenue rose 6.5% at Neogen (NEOG), alongside a swing to a quarterly loss.
Neogen (NEOG) reported a 6.5% increase in fiscal Q1 2027 revenue to $222.8 million, up from $209.2 million year-over-year. Despite the revenue growth, the company experienced a net loss of $11.9 million, or $0.05 per share, a significant shift from the prior year's net income of $36.3 million, which included a large gain from a business sale. The report also detailed the ongoing process of selling its Genomics business to Zoetis for $160.0 million and addressed a voluntary product recall affecting approximately 133,000 units.
Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
Neogen announced its first-quarter fiscal year 2027 financial results, reporting revenue of $222.8 million, a 6.5% increase, and a net loss of $11.9 million. The company is on track with its Petrifilm manufacturing transition and has raised its fiscal year 2027 financial guidance for both revenue and Adjusted EBITDA, reflecting encouraging progress in its operational improvements and strategic initiatives.
Michael Burry Sees The Following Stocks At Most Risk Ahead Of Tax Loss Harvesting Season
Michael Burry has detailed his Q4 portfolio adjustments, strategically navigating tax-loss harvesting season by making temporary swaps and consolidating positions. He is positioning for a potential end to the AI boom and a revival in value equities, while also investing significantly in discounted Chinese stocks like BYD. Burry is cautious about Alibaba due to its AI infrastructure spending and is holding Fiserv despite a suboptimal entry point.
Klarna Group (NYSE:KLAR) Stock Moved Up to Hold by Wall Street Zen
Wall Street Zen upgraded Klarna Group (NYSE:KLAR) from a "sell" to a "hold" rating, aligning with MarketBeat's consensus "Hold" rating and an average price target of $27.79. Despite trading near its 12-month low of $12.06, the company exceeded quarterly earnings expectations, reporting $0.01 EPS against a forecasted loss of $0.06, with revenue up 26.6% year over year. Notably, CEO Sebastian Siemiatkowski purchased nearly $10 million in shares, increasing his ownership.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health, based on strong parasiticide trends observed in a recent survey of veterinary clinics. The survey indicated that broad-spectrum parasiticides are performing well, with 64% of clinics prescribing more than the previous year, and Elanco's Quattro and Zenrelia products showing strong, efficacy-driven adoption. This positive outlook for Elanco contrasts with some challenges faced by Zoetis, whose shares are trading near a 52-week low despite appearing undervalued by InvestingPro analysis.
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
The article analyzes the Q2 earnings performance of pharmaceuticals stocks, highlighting Jazz Pharmaceuticals (NASDAQ:JAZZ) as a strong performer with revenues up 15.5% year-on-year, though its stock price dipped post-earnings. Bristol-Myers Squibb (NYSE:BMY) also had an impressive quarter, while Zoetis (NYSE:ZTS) was the weakest performer with flat revenues and missed expectations. The pharmaceuticals sector as a whole reported strong Q2 results, with revenues beating estimates by 5.5%.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health (NYSE:ELAN) due to strong parasiticide trends. A recent survey of U.S. veterinary clinics indicated robust demand for broad-spectrum parasiticides, with 64% prescribing more than last year. The analyst also noted competitive pressures on Zoetis’s Simparica Trio are mainly economic, supporting Zoetis's gross-to-net strategy, while Elanco's products like Quattro and Zenrelia are gaining traction.
What Is Drawing Attention To Axogen (AXGN)?
Axogen (AXGN) has garnered attention due to recent share price movements, showing a decline over the past month and three months but significant gains over the last year. Despite the recent pullback, which has brought its price to approximately 11% below an estimated intrinsic value and 25% below the average analyst target, the company's valuation narrative suggests it is 19% undervalued at $53.22. However, the article also notes potential risks due to Axogen's reliance on its Avance Nerve Graft and a high P/S ratio compared to industry peers.
ABIVAX Société Anonyme (ENXTPA:ABVX) Following New Leadership Hires And Wider Losses Looks Undervalued
ABIVAX Société Anonyme (ENXTPA:ABVX) is considered undervalued despite recent leadership changes, wider first-half losses, and increased cash usage. The company's lead drug, obefazimod, has shown strong Phase 3 results for ulcerative colitis, and the company has secured sufficient funding to avoid immediate capital raises. While the stock trades at a steep discount to analyst targets, its P/B ratio is high compared to the broader French biotech sector, indicating split sentiment among investors.
Absci Stock In Focus As Phase 2 Trial Plan Takes Shape
Absci has detailed the plan for its global Phase 2 STORYLINE trial of ABS-201 for endometriosis, which will be a double-blind, randomized, placebo-controlled study targeting about 150 patients across at least 10 countries. This trial aims to test a differentiated, nonhormonal approach using Absci's generative AI engineered anti-PRLR antibody. The company's investment narrative heavily relies on the success of ABS-201, with minimal current revenue and ongoing losses, projecting significant revenue and earnings growth by 2029 if the trial proves successful.
Weekly Recap: Outlook reaffirmed; revenue down and Renal $3B market; pipeline
Zoetis, Inc. (ZTS) has reaffirmed its full-year outlook despite a decline in U.S. companion-animal demand and price cuts on Cerenia and Convenia due to generic competition. The company is focusing on its pipeline, which includes a product targeting a $3 billion renal market, diagnostics, biomarkers, and an oncology candidate with a potential for $1 billion in sales, with updates expected in November. Zoetis does not anticipate other major products facing generic competition before 2032.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages
Eleven ratings firms have given Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a "Reduce" recommendation, with an average 12-month price target of $23.57. Despite this cautious sentiment, the company reported stronger-than-expected quarterly results, with adjusted earnings of $0.66 per share and revenue of $5.55 billion. Institutional ownership of FMS stock has increased, although collective institutional holdings remain at 8.37%.
Veeco Instruments Inc. (NASDAQ:VECO) Stock Now Rated "Hold" by Wall Street Analysts
Veeco Instruments (NASDAQ:VECO) has received a consensus "Hold" rating from Wall Street analysts, with an average 12-month price target of $61.33, significantly above its current trading price of $45.45. The company recently surpassed quarterly earnings expectations, reporting $0.33 EPS and $193.48 million in revenue. Despite strong institutional ownership, recent insider sales by the CEO and CFO have been noted.
GAMCO Natural Resources, Gold & Income Trust Q2 2026 Commentary (GNT)
The GAMCO Natural Resources, Gold & Income Trust (GNT) Q2 2026 commentary highlights significant market declines in gold bullion, crude oil, and agribusiness, with gold down 14.1% and crude oil down 31.4%. GNT responded by increasing its cash position to 24% and maintaining diversified sector allocations across gold/base metals, agriculture, and energy to manage volatility. The fund also increased its monthly distribution to $0.06 and continued its covered call strategy to generate income despite market turmoil.